Sei Investments Co. Increases Position in United Therapeutics Corporation $UTHR

Sei Investments Co. boosted its position in United Therapeutics Corporation (NASDAQ:UTHR) by 5.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 28,421 shares of the biotechnology company’s stock after acquiring an additional 1,589 shares during the period. Sei Investments Co. owned about 0.07% of United Therapeutics worth $16,853,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Leuthold Group LLC boosted its stake in United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after buying an additional 3,126 shares during the last quarter. UBS Group AG lifted its holdings in shares of United Therapeutics by 45.3% during the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after acquiring an additional 70,445 shares during the period. Perpetual Ltd acquired a new stake in shares of United Therapeutics in the fourth quarter worth approximately $1,059,000. Brookstone Capital Management grew its holdings in United Therapeutics by 25.4% in the fourth quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company’s stock valued at $3,227,000 after purchasing an additional 1,342 shares during the period. Finally, Nicholas Investment Partners LP increased its position in United Therapeutics by 478.5% during the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after purchasing an additional 3,766 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of research analyst reports. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a report on Thursday, May 7th. JPMorgan Chase & Co. lifted their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Finally, Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective on the stock. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $648.33.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $578.58, for a total value of $5,785,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,921,276.08. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 502,833 shares of company stock worth $279,835,157 in the last 90 days. Insiders own 8.60% of the company’s stock.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Promising ralinepag trial results: The Lancet published full results from United Therapeutics’ ADVANCE OUTCOMES study. Investigational pulmonary arterial hypertension treatment ralinepag reduced the risk of clinical worsening by 55% versus placebo, improving the company’s potential pipeline outlook. Ralinepag is not yet approved by the FDA, so regulatory and commercialization risks remain. United Therapeutics Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
• Positive Sentiment: Analyst support remains strong: Eleven analysts rate UTHR a Buy and two rate it a Hold, producing a consensus “Moderate Buy” rating. The average price target is $648.33, with JPMorgan recently raising its target to $687 and HC Wainwright increasing its target to $660. United Therapeutics Given Average Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Institutional ownership is high: Hedge funds and other institutional investors own approximately 94.1% of UTHR’s shares. Several institutions increased their positions during the second quarter, signaling continued professional-investor interest, although this does not guarantee further gains. United Therapeutics Insider Trading Report
• Negative Sentiment: CEO stock sale may pressure sentiment: CEO Martine Rothblatt sold 9,500 shares for roughly $5.04 million, reducing her direct stake by 2.84%. She still owns a substantial position, so the transaction may reflect liquidity or diversification rather than a negative view of the business, but insider selling can weigh on investor confidence. Insider Selling United Therapeutics CEO Sells Stock
• Negative Sentiment: Recent operating results were below expectations: United Therapeutics previously reported quarterly earnings and revenue below consensus, with revenue declining 1.6% year over year. That performance remains a concern despite the company’s strong profitability and promising pipeline.

United Therapeutics Trading Up 0.2%

Shares of UTHR stock opened at $524.70 on Thursday. The company has a market cap of $22.27 billion, a PE ratio of 19.37, a P/E/G ratio of 1.75 and a beta of 0.58. The company’s fifty day simple moving average is $545.45 and its 200-day simple moving average is $532.24. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same period last year, the company posted $6.63 earnings per share. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. Equities research analysts expect that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.